3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now

The article argues that Pfizer, Novo Nordisk, and PDD Holdings are trading at unusually low valuations, at about 9x, less than 14x, and 8x forward earnings, respectively. Pfizer is highlighted for a 6.8% dividend yield and a growing pipeline, Novo for GLP-1 growth potential despite 4% adjusted sales weakness in Q1, and PDD for 12% revenue growth to roughly $17.7 billion despite tariff pressure. The piece is bullish on long-term upside, but it is largely valuation commentary rather than a new company-specific catalyst.

Analysis

This is less a clean “value” setup than a dispersion trade across three different policy/competition regimes. The market is penalizing all three for near-term uncertainty, but the earnings asymmetry is not the same: PFE is a cash-return story with optionality on pipeline execution, NVO is a duration asset where pricing pressure can temporarily mask a still-dominant franchise, and PDD is a macro/tariff beta name whose multiple can re-rate fastest if trade friction eases. In other words, the discount is real, but the catalyst quality differs materially.

The most interesting second-order effect is competitive: if NVO’s next-gen obesity assets gain traction, the pressure moves beyond Lilly and into payer behavior, forcing broader formulary re-pricing that can lift the entire GLP-1 category while compressing near-term margins. For PFE, the key is not just pipeline replacement but capital allocation; at this valuation, buybacks/dividend support can offset some patent-cliff anxiety, but only if operating cash flow stays stable over the next 2-4 quarters. PDD is the cleanest sentiment reversal trade because its earnings are most levered to incremental trade normalization, but it is also the most exposed to headline risk and position crowding.

Consensus is likely over-discounting the optionality embedded in “bad news already priced in” names, but underestimating how long each catalyst can take to show up in reported numbers. The market can keep compressing these multiples for months if guidance stays cautious, so timing matters: these are not all-in longs, they are staged entries around event windows and policy shifts. The best edge is pairing the names with structurally lower regulatory or tariff beta rather than owning them outright on a standalone basis.

Key Decisions for Investors

• Long PFE vs short XBI for 3-6 months: express the view that cash-flow durability and capital returns are being mispriced relative to biotech’s higher clinical binary risk; target modest multiple rerating, but cut if pipeline headlines fail to improve by next earnings.
• Initiate a starter long NVO over 6-12 months, preferably on weakness: thesis is that next-gen obesity assets can offset current pricing pressure; use a time horizon long enough for launch/label expansion evidence, with downside bounded by franchise quality but upside capped if Lilly stays ahead.
• Trade PDD as a tactical event-driven long for 1-3 months only if trade rhetoric improves: best risk/reward is buying pessimism ahead of tariff relief headlines; if no policy progress, treat as a fade and avoid duration exposure.
• Pair long NVO / short PFE for relative value: own the higher-quality growth compounder against the mature cash-return name; this isolates obesity pipeline upside while limiting balance-sheet and patent-cliff noise.
• Avoid full-size outright exposure until after the next earnings cycle: these are valuation dislocations, but the market will likely demand at least one clean guide-up or policy catalyst before rewarding them.